Palantir Breaks 188 Resistance; Golden Cross Signals Uptrend Continuation
Sep 23, 2026, 1:53 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
A breakout above a multi-month resistance (188) with a confirmed support level typically attracts momentum buyers and could accelerate toward the next resistance around 199 and higher, especially with a bullish golden cross and positive momentum indicators like RSI and MACD.
AI summary
What happened, with direct paths to the underlying reporting
Palantir cleared the $188 resistance and held it as support, signaling a breakout. The stock’s 50/200-day golden cross reinforces the early uptrend, with the next hurdle near $199 and potential move toward the all-time high of $207.52 if momentum persists. Bullish RSI and MACD readings suggest continued upside in the near term.
Palantir breaks above $188 resistance and holds as support.
Golden cross: 50-day above 200-day signals developing uptrend.
Next resistance seen near $199; all-time close high at $207.52.
RSI 67.3 and MACD positive support continued upside.
Price up 3.63% to $191.71; momentum remains bullish.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Palantir extended its rally to record highs on renewed conviction around its sovereign AI strategy, reinforced by a Goldman Sachs upgrade to Buy with a $230 target. The company po…
Goldman Sachs upgraded Palantir to Buy, citing expanding sovereign AI demand and custom-built applications that could enlarge its addressable market. The upgrade reinforces recent…
Palantir faces renewed UK political risk as Labour-linked lobbying surfaces around its £330m NHS England data platform contract. The break clause in Feb 2027 and protests over Pal…
More than 44,000 formal objections to NHS England's FDP using Palantir AI have raised regulatory and reputational risk for PLTR. The NHS deal is valued at £330 million over seven…